• Policy
• Vabysmo·Evrysdi, listed as reimbursement
• by Lee, Tak-Sun Sep 22, 2023 05:41am

• Policy
• Bioequivalence reevals speed up in line with drug price reev
• by Lee, Hye-Kyung Sep 21, 2023 05:24am

• Policy
• Pseudoephedrine price negotiations have been concluded
• by Lee, Tak-Sun Sep 21, 2023 05:24am

• Policy
• ‘Introduce a Korean Cancer Moonshot Plan for patients'
• by Lee, Jeong-Hwan Sep 21, 2023 05:24am

• Opinion
• [Reporter’s View] Biobetters to prosper with better prices
• by Eo, Yun-Ho Sep 21, 2023 05:23am

• Policy
• Generics for Janumet competition begins in earnest in Oct.
• by Lee, Tak-Sun Sep 21, 2023 05:23am

• Opinion
• [Reporter’s View] Industry suffers from ‘Re-eval Neurosis'
• by Kim, Jin-Gu Sep 20, 2023 05:36am

• Policy
• High-priced drugs need adjustment from the approval stage
• by Lee, Tak-Sun Sep 20, 2023 05:36am

• Policy
• The NHIS begins negotiations to increase the size of PSE
• by Lee, Tak-Sun Sep 20, 2023 05:36am

• Company
• A new drug for optic shylomyelitis is necessary
• by Eo, Yun-Ho Sep 20, 2023 05:35am